Shares of ObsEva SA (NASDAQ:OBSV) have received a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy recommendation.

Analysts have set a 1-year consensus price objective of $24.00 for the company and are predicting that the company will post ($0.48) earnings per share for the current quarter, according to Zacks. Zacks has also given ObsEva SA an industry rank of 108 out of 265 based on the ratings given to its competitors.

A number of research firms have recently weighed in on OBSV. Zacks Investment Research raised ObsEva SA from a “sell” rating to a “hold” rating in a research note on Wednesday, July 19th. HC Wainwright assumed coverage on ObsEva SA in a research report on Thursday, June 29th. They issued a “buy” rating and a $27.00 target price on the stock. Finally, Credit Suisse Group reiterated an “outperform” rating and issued a $27.00 target price on shares of ObsEva SA in a research report on Tuesday, April 18th.

Large investors have recently bought and sold shares of the company. UBS Oconnor LLC purchased a new stake in ObsEva SA during the first quarter worth approximately $1,017,000. Baker Avenue Asset Management LP purchased a new stake in ObsEva SA during the first quarter worth approximately $104,000. Paloma Partners Management Co purchased a new stake in ObsEva SA during the first quarter worth approximately $131,000. Iguana Healthcare Management LLC purchased a new stake in ObsEva SA during the first quarter worth approximately $260,000. Finally, Nexthera Capital LP purchased a new stake in ObsEva SA during the first quarter worth approximately $521,000. Institutional investors own 49.11% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/08/07/zacks-obseva-sa-nasdaqobsv-given-consensus-recommendation-of-by-brokerages.html.

ObsEva SA (NASDAQ:OBSV) traded up 0.689% on Friday, hitting $8.035. The stock had a trading volume of 26,523 shares. The company’s market capitalization is $213.92 million. The firm has a 50-day moving average of $7.40 and a 200 day moving average of $9.26. ObsEva SA has a 52 week low of $5.00 and a 52 week high of $14.70.

ObsEva SA (NASDAQ:OBSV) last released its quarterly earnings data on Thursday, May 18th. The company reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by $0.17. On average, analysts predict that ObsEva SA will post ($2.04) earnings per share for the current year.

ObsEva SA Company Profile

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.

Get a free copy of the Zacks research report on ObsEva SA (OBSV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ObsEva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva SA and related companies with MarketBeat.com's FREE daily email newsletter.